C-Met Inhibitor HS-10241 clinical trials
Also written HS-10241.
How each study uses c-Met Inhibitor HS-10241 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the c-Met Inhibitor HS-10241 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- HS-10241
- 6
Studies by the year they started
7 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2016 | 2 |
| 2017 | 1 |
| 2019 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Jiangsu Hansoh Pharmaceutical Co., Ltd. (6) · Atridia Pty Ltd. (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses c-Met Inhibitor HS-10241 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Pharmacokinetic Study of HS-10241 Tablets in Subjects with Hepatic Impairment and Normal Hepatic FunctionNot yet recruitingPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT06823245Written as HS-10241
- A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI TherapyNot yet recruitingPhase 3Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT06110663Written as HS-10241+ Almonertinib
- Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLCStatus unknownPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT05430386Written as HS-10241
- A Phase I Trial of HS-10241 in Solid TumorsCompletedPhase 1Atridia Pty Ltd.NCT02759640Written as HS-10241
- PhaseⅠStudy of the HS-10241 in Patients With Advanced Solid TumorsStatus unknownPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT04477057Written as HS-10241
- Tolerability, Safety, Pharmacokinetics and Efficacy of HS-10241 Single Agent or Combined With Apatinib in Patients With Advanced Solid TumorsStatus unknownPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT03243643Written as HS-10241
- A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid TumoursStatus unknownPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT02977364Written as HS-10241